Genmab Shares Rise on Goldman Sachs Buy Upgrade
By EC Assets · Published · Updated
Genmab shares rose following a stock upgrade by Goldman Sachs. The investment bank raised its rating on Genmab to Buy. This upgrade reflects increased confidence in the company's product pipeline. The positive assessment from Goldman Sachs highlights the potential within Genmab's development programs. The upgrade signals a more optimistic outlook on the biotechnology firm's future prospects. This article is intended for informational purposes only. It does not constitute investment advice.
Stay informed
Market commentary, firm news and research from EC Assets — direct to your inbox.